J&J’s coronavirus vaccine is ahead of schedule
Johnson & Johnson is moving up the timeline for its in-development coronavirus vaccine, edging closer to competitors in what will amount to an NIH-sponsored bake-off.
The company said yesterday that it will begin Phase 1 trials in July, two months ahead of its earlier projection. Meanwhile, the NIH told the Wall Street Journal that it has laid out a plan to fund and conduct Phase 3 trials for vaccines from Moderna, AstraZeneca, and J&J. Moderna’s study will begin in July, followed by AstraZeneca in August and J&J in September.
The trio of trials will be a massive undertaking, enrolling nearly 100,000 people at more than 100 sites in total. And the results will provide plenty to talk about.
Scientists warn against cross-trial comparisons, but it’ll be impossible not to consider the datasets against one another. And, if one or more of the vaccines ends up working, the pricing conversation will take on a novel dimension. When the federal government funds the entire Phase 3 process, how much can companies justify charging for the finished product?
The company said yesterday that it will begin Phase 1 trials in July, two months ahead of its earlier projection. Meanwhile, the NIH told the Wall Street Journal that it has laid out a plan to fund and conduct Phase 3 trials for vaccines from Moderna, AstraZeneca, and J&J. Moderna’s study will begin in July, followed by AstraZeneca in August and J&J in September.
The trio of trials will be a massive undertaking, enrolling nearly 100,000 people at more than 100 sites in total. And the results will provide plenty to talk about.
Scientists warn against cross-trial comparisons, but it’ll be impossible not to consider the datasets against one another. And, if one or more of the vaccines ends up working, the pricing conversation will take on a novel dimension. When the federal government funds the entire Phase 3 process, how much can companies justify charging for the finished product?
No hay comentarios:
Publicar un comentario